(firstQuint)Lamivudine(LAM) Good Responder Study.

 This is to evaluate the proportion of subjects who show good responses to LAM treatment such as HBV DNA negativity, HBV DNA less than 4 log, no resistant mutation, HBeAg seroconversion and normalization of ALT in naive CHB patients with certain pre-treatment characteristics, i.

e.

 HBV DNA less than 9log copies per ml and ALT more than 2 times ULN in HBeAg positive subjects, HBV DNA less than 7log copies per ml and elevated ALT in HBeAg negative subjects.

.

 Lamivudine(LAM) Good Responder Study@highlight

This is to evaluate the proportion of subjects who show good responses to LAM treatment in Korea.

